Literature DB >> 15316504

CTLA-4 polymorphisms in allergy and asthma and the TH1/ TH2 paradigm.

Monica Cheng Munthe-Kaas1, Kai Håkon Carlsen, Peter J Helms, Jorrit Gerritsen, Moira Whyte, Marlies Feijen, Beate Skinningsrud, Margaret Main, Georges Ng Man Kwong, Benedicte A Lie, Karin C Lødrup Carlsen, Dag E Undlien.   

Abstract

BACKGROUND: Several genomic regions are reported to be associated with the development of asthma and allergy, including chromosome 2q33. This region harbors the candidate gene cytotoxic T-lymphocyte antigen 4 (CTLA-4), an important regulator of T-cell activation and differentiation.
OBJECTIVE: We sought to explore possible associations between CTLA-4 polymorphisms and allergy and asthma.
METHODS: Seven single nucleotide polymorphisms (SNPs; MH30, -1147CT, +49AG, CT60, JO31, JO30, JO27_1) in CTLA-4 were analyzed for associations with total serum IgE, allergic sensitization (positive skin prick test to common allergens), bronchial hyperresponsiveness (BHR) to methacholine, asthma, and lung function (FEV1 % of predicted) in 364 asthmatic families from 3 European countries.
RESULTS: Transmission disequilibrium test analysis showed that several SNPs were significantly associated with serum IgE levels, allergy, asthma, and FEV1 % predicted below 80%, but not with BHR, and CTLA-4 polymorphisms of potentially direct pathogenic significance in atopic disorders were identified.
CONCLUSION: We identified associations between 4 newly discovered SNPs in the CTLA-4 gene and serum IgE levels, allergy, asthma, and reduced lung function, but not BHR, suggesting an important role for CTLA-4 in atopy and reduced lung function in asthmatic subjects rather than asthma per se. The particular SNP alleles found positively associated with our phenotypes were recently shown to be associated negatively with autoimmune disorders. Although a skewing toward a TH1 reactivity pattern is believed to characterize autoimmune diseases, atopic diseases are considered TH2-mediated. Hence, our data suggest a role for CTLA-4 polymorphisms in determining the TH1/TH2 balance and identify CTLA-4 signaling as a potential therapeutic target in atopic disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316504     DOI: 10.1016/j.jaci.2004.03.050

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

Review 1.  Asthma from a pharmacogenomic point of view.

Authors:  C Szalai; I Ungvári; L Pelyhe; G Tölgyesi; A Falus
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

2.  Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

Authors:  Heather M Gibson; Carrie J Hedgcock; Barbara M Aufiero; Adam J Wilson; Mikehl S Hafner; George C Tsokos; Henry K Wong
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 3.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

4.  Maternal microchimerism protects against the development of asthma.

Authors:  Emma E Thompson; Rachel A Myers; Gaixin Du; Tessa M Aydelotte; Christopher J Tisler; Debra A Stern; Michael D Evans; Penelope E Graves; Daniel J Jackson; Fernando D Martinez; James E Gern; Anne L Wright; Robert F Lemanske; Carole Ober
Journal:  J Allergy Clin Immunol       Date:  2013-02-21       Impact factor: 10.793

5.  Surfactant protein D-mediated decrease of allergen-induced inflammation is dependent upon CTLA4.

Authors:  Ko-Wei Lin; Kai Yu Jen; Carlos Jose Suarez; Erika C Crouch; David L Perkins; Patricia W Finn
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

6.  The CTLA-4 +49 A/G and -318 C/T polymorphisms and susceptibility to asthma: a meta-analysis.

Authors:  Young Ho Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

7.  CTLA-4, position 49 A/G polymorphism associated with coronary artery lesions in Kawasaki disease.

Authors:  Ho-Chang Kuo; Chi-Di Liang; Hong-Ren Yu; Chih-Lu Wang; I-Chun Lin; Chieh-An Liu; Jen-Chieh Chang; Chiu-Ping Lee; Wei-Chiao Chang; Kuender D Yang
Journal:  J Clin Immunol       Date:  2010-11-17       Impact factor: 8.317

Review 8.  Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

Authors:  Shaheen Khan; David E Gerber
Journal:  Semin Cancer Biol       Date:  2019-07-19       Impact factor: 15.707

9.  CTLA4 polymorphism and primary Sjögren's syndrome.

Authors:  Susan Lester; Sarah Downie-Doyle; Maureen Rischmueller
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease.

Authors:  Lidia Karabon; Agata Kosmaczewska; Malgorzata Bilinska; Edyta Pawlak; Lidia Ciszak; Anna Jedynak; Anna Jonkisz; Leszek Noga; Anna Pokryszko-Dragan; Magdalena Koszewicz; Irena Frydecka
Journal:  Immunology       Date:  2009-02-17       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.